RUNX2 and CD4+/CD56+ hematodermic neoplasm: Since t(6;8)(p21;q24) is specific to BPDCN, using functional genomic assays combined with a mouse model, we elucidated the molecular mechanisms responsible for the initiation and progression of BPDCN, which are driven by the MYC oncogene and pDC-lineage transcription factor RUNX2.